Related Experiment Video

Updated: Nov 10, 2025

Lung CT Segmentation to Identify Consolidations and Ground Glass Areas for Quantitative Assesment of SARS-CoV Pneumonia
08:05

Lung CT Segmentation to Identify Consolidations and Ground Glass Areas for Quantitative Assesment of SARS-CoV Pneumonia

Published on: December 19, 2020

14.4K

COVID-19 infection in patients with connective tissue disease: A multicity study in Hubei province, China

Cong Ye1, Jixin Zhong1, Shaozhe Cai1

  • 1Department of Rheumatology and Immunology Tongji Hospital Tongji Medical College of Huazhong University of Science and Technology Wuhan Hubei China.

Medcomm
|April 6, 2021
PubMed

Insights

Connective tissue disease (CTD) patients experienced more severe COVID-19 outcomes compared to gout and ankylosing spondylitis (AS) patients. Hydroxychloroquine and glucocorticoids may reduce COVID-19 severity in rheumatic patients.

Area of Science:

  • Rheumatology
  • Infectious Diseases
  • COVID-19 Research

Background:

  • Rheumatic disease patients on immunosuppressants face higher infection risks.
  • Specific risks for COVID-19 within rheumatic disease subtypes remain unclear.

Purpose of the Study:

  • To investigate COVID-19 severity and outcomes in different rheumatic disease subcategories.
  • To identify risk factors and protective treatments for COVID-19 in rheumatic patients.

Main Methods:

  • Retrospective analysis of 100 rheumatic patients from 18,786 hospitalized COVID-19 patients.
  • Data collected included demographics, medical history, disease severity, lab tests, and treatments.
  • Comparison of outcomes between connective tissue disease (CTD), gout, and ankylosing spondylitis (AS) patients.

Main Results:

  • Connective tissue disease (CTD) patients showed a trend towards more severe COVID-19 compared to gout and AS patients (p=0.081).
  • CTD patients exhibited lower lymphocyte counts, hemoglobin, and platelet counts.
  • Hydroxychloroquine and low-to-medium dose glucocorticoids before diagnosis were associated with reduced progression to severe/critical COVID-19 (p=0.001 and p=0.006, respectively).

Conclusions:

  • COVID-19 may present more severely in connective tissue disease (CTD) patients compared to those with ankylosing spondylitis (AS) or gout.
  • Hydroxychloroquine and glucocorticoid therapy may mitigate severe COVID-19 progression in rheumatic patients.

Keywords:
COVID‐19SARS‐CoV‐2connective tissue diseasehydroxychloroquinerheumatic disease

More Related Videos

Digital Analysis of Immunostaining of ZW10 Interacting Protein in Human Lung Tissues07:40

Digital Analysis of Immunostaining of ZW10 Interacting Protein in Human Lung Tissues

Published on: May 1, 2019

5.5K

Related Concept Videos

Connective Tissue Cell Types01:22

Connective Tissue Cell Types

Connective tissue develops from the mesoderm of a developing embryo and consists of cells, fibers, and ground substance: a gel-like material containing large complexes of carbohydrates and proteins. Connective tissue was first identified as a separate tissue family in the 18th century, and Johannes Peter Muller coined the term connective tissue.
Fat cells (adipocytes), smooth muscle cells (myoblasts), and bone cells (osteoblasts) are some connective tissue cell types. Some immune system cells...
3.7K
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
458
Chronic Obstructive Pulmonary Disease01:22

Chronic Obstructive Pulmonary Disease

COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
1.8K
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies01:22

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
197
Pulmonary Tuberculosis III01:31

Pulmonary Tuberculosis III

Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
573
COPD: Pathogenesis and Clinical Features01:20

COPD: Pathogenesis and Clinical Features

Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
1.5K